A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome

Table 2 Characteristics of studies comparing mebeverine and placebo included in meta-analysis

Study	Treatment duration (wk)	Dosage		IBS Subtype	Sex (F/M)	Mean age (yr)
		Placebo	Mebeverine			Placebo	Mebeverine
Kruis et al[21] 1986	4-8-12-16	Placebo open branch n = 40	100 mg qid n = 40	All subtype	23/17	F = 43	F = 43
	Wheat bran (12)	Wheat bran 15 g/d n = 40				M = 41	M = 41
Connell[13] 1965	12	n = 20	400 mg/d n = 20	All subtype	25/15	40	40
Tasman-Jones[22] 1973	4	n = 12	400 mg/d n = 12	All subtype	14/10	43	43
Berthelot et al[11] 1981	8	n = 33	400 mg/d n = 36	All subtype	74/37	56	56
Secco et al[19] 1983	4	n = 15	400 mg/d n= 15	All subtype	15/15	45	45
Enck et al[23] 2005	16	Placebo n = 40	n = 40	All subtype		43	36
		Dietary treatment n = 40